Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and Multiple System Atrophy.

Background. Parkinson's disease (PD) is a progressive neurodegenerative disorder which may be misdiagnosed with atypical conditions such as Multiple System Atrophy (MSA), due to overlapping clinical features. MicroRNAs (miRNAs) are small noncoding RNAs with a key role in post-transcriptional ge...

Full description

Bibliographic Details
Main Authors: Annamaria eVallelunga, Marco eRagusa, Stefania eDi Mauro, Tommaso eIannitti, Manuela ePilleri, Roberta eBiundo, Luca eWeis, Cinzia eDi Pietro, Angela eDe Iuliis, Alessandra eNicoletti, Mario eZappia, Michele ePurrello, Angelo eAntonini
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-06-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fncel.2014.00156/full
Description
Summary:Background. Parkinson's disease (PD) is a progressive neurodegenerative disorder which may be misdiagnosed with atypical conditions such as Multiple System Atrophy (MSA), due to overlapping clinical features. MicroRNAs (miRNAs) are small noncoding RNAs with a key role in post-transcriptional gene regulation. We hypothesized that identification of a distinct set of circulating miRNAs (cmiRNAs) could distinguish patients affected by PD from MSA and healthy individuals. Results. Using TaqMan Low Density Array technology, we analysed 754 miRNAs and found 9 cmiRNAs differentially expressed in PD and MSA patients compared to healthy controls. We also validated a set of 4 differentially expressed cmiRNAs in PD and MSA patients versus controls. More specifically, miR-339-5p was downregulated, whereas miR-223*, miR-324-3p and mir-24 were upregulated in both diseases. We found cmiRNAs specifically deregulated in PD (downregulation of miR-30c and miR-148b) and in MSA (upregulation of miR-148b). Finally, comparing MSA and PD, we identified 3 upregulated cmiRNAs in MSA serum (miR-24, miR-34b, miR-148b). Conclusions. Our results suggest that cmiRNA signatures discriminate PD from MSA patients and healthy controls and may be considered specific, non-invasive biomarkers for differential diagnosis.
ISSN:1662-5102